After a short stay in the biotech world, Dietmar Berger is back in Big Pharma R&D — and he's taking a prominent place in Sanofi
Dietmar Berger’s stretch in biotech R&D turned into little more than a pit stop between prominent Big Pharma posts.
Sanofi is spreading the word that Berger, who just bounced from Atara Biotherapeutics, has been named head of global development for Sanofi.
The Paris-based Sanofi Tweeted the news on Wednesday. And his LinkedIn account notes that the longtime West Coast player is now based in Cambridge, MA, where Sanofi has been concentrating its R&D forces.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.